Bispecific Breakthrough | Merus N.V. leads in developing innovative bispecific antibody therapeutics, targeting multiple cancer pathways simultaneously with promising results. |
Zenocutuzumab's Potential | Explore the broad efficacy of Merus's lead candidate across various tumor types, with potential BLA filings for lung and pancreatic cancers in 2024. |
Diverse Pipeline Progress | Delve into Merus's robust pipeline, including MCLA-145, MCLA-129, and petosemtamab, showcasing encouraging efficacy in clinical trials across multiple cancers. |
Market Outlook | Analysts project revenue growth from $44M in 2023 to $112M in 2025, with a $58 price target, reflecting Merus's potential in the expanding oncology market. |
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Metrics to compare | MRUS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMRUSPeersSector | |
---|---|---|---|---|
P/E Ratio | −21.2x | −3.0x | −0.6x | |
PEG Ratio | −0.87 | 0.00 | 0.00 | |
Price/Book | 4.8x | 2.7x | 2.6x | |
Price / LTM Sales | 101.0x | 8.7x | 3.3x | |
Upside (Analyst Target) | 68.9% | 254.2% | 49.0% | |
Fair Value Upside | Unlock | 23.3% | 7.7% | Unlock |